Real-time disaster intelligence, alerts, and response tools.
Wednesday, April 29, 2026
[ad_1] 83% (78/94) of patients demonstrated ocular tumor shrinkage, with 54% (51/94) achieving ≥20% tumor shrinkage 57% (24/42) eye preservation rate in enucleation (EN) recommended patients, which increased to 95% (19/20) in patients achieving ≥20% […]
[ad_1] Orphan Drug Designation granted to CK0803 for Amyotrophic Lateral Sclerosis CK0803 is CNS Homing Tregs expressing CXCR3hi, CXCR7+, LFA1+ CK0803 is planned for Randomized Placebo Control Trial in 2026 HOUSTON, Oct. 20, 2025 /PRNewswire/ — Cellenkos® Inc., […]
[ad_1] Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged […]
[ad_1] HONG KONG, Oct. 19, 2025 /PRNewswire/ — On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 […]
[ad_1] Latest Data from Phase I/II Study Reported in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and Published Concurrently in Nature Medicine VT3989 Achieves 32% Overall Response Rate, 86% […]
